| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
ZLAB
Zai Lab
|
Oct 25, 2026 | BUY |
Strong Buy
+170.4% avg upside
13 analysts
|
$37.00
67.56% Upside
|
+1.1% | · |
|
CELC
Celcuity
|
Oct 22, 2026 | BUY |
Strong Buy
+82.6% avg upside
18 analysts
|
$140.00
102.46% Upside
|
-1.8% | · |
|
ASND
Ascendis Pharma
|
Sep 25, 2026 | BUY |
Strong Buy
+12.2% avg upside
29 analysts
|
$300.00
19.33% Upside
|
+22.1% | · |
|
NUVB
Nuvation Bio
|
Aug 21, 2026 | BUY |
Strong Buy
+178.0% avg upside
18 analysts
|
$12.00
152.06% Upside
|
-42.4% | · |
|
REPL
Replimune Group
|
Jul 31, 2026 | BUY |
Strong Buy
+40.9% avg upside
14 analysts
|
— | +95.5% | · |
|
ANL
Adlai Nortye Ltd. Sponsored ADR
|
Jul 16, 2026 | BUY |
Strong Buy
+181.2% avg upside
9 analysts
|
— | -7.7% | · |
|
IMRX
Immuneering
|
Jul 08, 2026 | BUY |
Strong Buy
+379.3% avg upside
12 analysts
|
$17.00
353.98% Upside
|
-32.9% | · |
|
FTH
Faeth Therapeutics
|
Jun 03, 2026 | BUY |
Strong Buy
+160.3% avg upside
22 analysts
|
— | +39.2% | · |
|
CRIS
Curis
|
Mar 27, 2026 | HOLD |
Strong Buy
+2085.2% avg upside
12 analysts
|
— | · | · |
|
TYRA
Tyra Bioscience
|
Mar 04, 2026 | BUY |
Strong Buy
+107.4% avg upside
17 analysts
|
— | -43.2% | · |
|
AVBP
ArriVent BioPharma, Inc.
|
Dec 22, 2025 | BUY |
Strong Buy
+89.4% avg upside
15 analysts
|
— | -41.9% | · |
|
CMPX
Compass Therapeutics
|
Dec 03, 2025 | BUY |
Strong Buy
+831.7% avg upside
20 analysts
|
— | -85.4% | · |
|
RCUS
Arcus Biosciences
|
Oct 08, 2025 | BUY |
Strong Buy
+98.9% avg upside
22 analysts
|
— | +58.3% | · |
|
CNTX
Context Therapeutics
|
Oct 02, 2025 | BUY |
Strong Buy
+2537.5% avg upside
12 analysts
|
— | -69.0% | · |
|
ARVN
Arvinas Holding Company
|
Sep 18, 2025 | BUY |
Buy
+257.9% avg upside
28 analysts
|
— | +7.4% | · |
|
IDYA
IDEAYA Biosciences
|
Sep 09, 2025 | BUY |
Strong Buy
+48.3% avg upside
31 analysts
|
— | +55.0% | · |
|
KURA
Kura Oncology
|
Jun 26, 2025 | BUY |
Strong Buy
+155.5% avg upside
27 analysts
|
— | +90.2% | · |
|
CRVS
Corvus Pharmaceuticals
|
Jun 12, 2025 | BUY |
Strong Buy
+151.5% avg upside
14 analysts
|
— | +181.4% | · |
|
ACRV
Acrivon Therapeutics, Inc.
|
May 15, 2025 | BUY |
Strong Buy
+761.9% avg upside
13 analysts
|
— | +60.9% | · |
|
AFMDQ
Affimed
|
May 14, 2025 | HOLD |
Buy
+1359021112.1% avg upside
16 analysts
|
— | · | · |
|
TARA
Protara Therapeutics
|
Mar 14, 2025 | BUY |
Strong Buy
+1907.3% avg upside
21 analysts
|
— | +22.0% | · |
|
ALXO
ALX Oncology Holdings
|
Jan 24, 2025 | BUY |
Strong Buy
+1370.9% avg upside
11 analysts
|
— | -7.3% | · |
|
BCYC
Bicycle Therapeutics
|
Jun 03, 2024 | BUY |
Strong Buy
+557.2% avg upside
21 analysts
|
— | -64.0% | · |
|
ALP
Alpha Compute
|
Aug 30, 2023 | BUY |
Strong Buy
+974.7% avg upside
7 analysts
|
$11.00
235.38% Upside
|
· | · |
|
FATE
Fate Therapeutics
|
Aug 09, 2023 | HOLD |
Buy
+482.8% avg upside
31 analysts
|
$5.00
140.41% Upside
|
-0.9% | · |
|
VINC
Vincerx Pharma Inc
|
Aug 07, 2023 | BUY |
Strong Buy
+89900.0% avg upside
6 analysts
|
$5.00
33233.43% Upside
|
· | · |
|
NKTX
Nkarta
|
Aug 12, 2022 | BUY |
Strong Buy
+1080.5% avg upside
16 analysts
|
$38.00
2335.91% Upside
|
-88.5% | · |
|
SLS
SELLAS Life Sciences Group
|
Jun 28, 2022 | BUY |
Strong Buy
+606.8% avg upside
16 analysts
|
$6.00
38.06% Downside
|
-26.7% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.